NOLCA symposium on oncological treatment of advanced/metastatic hepatocellular carcinoma (HCC) and biliary tract treatment (BTC)

A hybrid meeting on

19 September at 13:00-15:00 (EEST)

Chairs Pia Österlund and Merete Krogh

13:00          Treatability of HCC and BTC patients, Kaisa Lehtomäki

13:10          Optimizing the underlying liver disease for oncological treatment, Maria Reig

13:30          Oncological treatment of HCC,  Lorenza Rimassa

14:00          Oncological treatment of BTC,  Arndt Vogel 

14:30         Managing IO-toxicity, Gustav Ullenhag

14:55         Final remarks, Pia Österlund

15:00         Adjourn

Program

Optimal use of the ToolboX for HCC treatment

Welcome and introduction, Pia Österlund(FI/S)

Case 1: Transplantation or ablation. Or: Too early to consider transplantation? Per Stål (S)

Case 2: Downstaging to transplantation. Or: Too advanced to consider transplantation?

Aki Uutela (FI)

Immunotherapy in the setting of liver transplantation – mission (im)possible?

Ghassan Abou-Alfa (US)

Discussion moderated by Pia Österlund

Learning goals:

·   Understanding of the management of HCC patients on the fringe of transplant eligibility.

·   Be aware of the challenges with immunotherapy in the liver transplant setting.

                                                                                                                                       This webinar was supported by:

Eisai and AstraZeneca have had no influence on content of the agenda, nor speakers. The content is the property of the speakers. NOLCA and speakers are fully responsible for the medical and scientific content of the webinar.